1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
- Contribution to journal › Article
- 2018
-
Mark
Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study
- Contribution to journal › Article
- 2009
-
Mark
High-Resolution Genomic Profiling of Carboplatin Resistance in Early-Stage Epithelial Ovarian Carcinoma
Osterberg, L. ; Levan, K. ; Partheen, K. ; Staaf, Johan LU
; Sundfeldt, K.
and Horvath, G.
(2009)
In Cytogenetic and Genome Research
125(1).
p.8-18
- Contribution to journal › Article
- 2008
-
Mark
Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel - long-term follow-up
- Contribution to journal › Article
-
Mark
Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
- Contribution to journal › Article